About the Authors

David M. Rissin

Contributed equally to this work with: David M. Rissin, Barbara López-Longarela

Affiliation Quanterix Corporation, Lexington, Massachusetts, United States of America

Barbara López-Longarela

Contributed equally to this work with: David M. Rissin, Barbara López-Longarela

Affiliation DestiNA Genomics Ltd., Edinburgh, United Kingdom; DestiNA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, Granada, Spain

Salvatore Pernagallo

Affiliation DestiNA Genomics Ltd., Edinburgh, United Kingdom; DestiNA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, Granada, Spain

Hugh Ilyine

Affiliation DestiNA Genomics Ltd., Edinburgh, United Kingdom; DestiNA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, Granada, Spain

A. D. Bastiaan Vliegenthart

Affiliation Edinburgh University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, Edinburgh, United Kingdom

James W. Dear

Affiliation Edinburgh University/BHF Centre for Cardiovascular Science, The Queen's Medical Research Institute, Edinburgh, United Kingdom

Juan J. Díaz-Mochón

dduffy@quanterix.com (DCD.); juan@destinagenomics.com (JJD-M)

Affiliations DestiNA Genomics Ltd., Edinburgh, United Kingdom; DestiNA Genomica S.L. Parque Tecnológico Ciencias de la Salud (PTS), Avenida de la Innovación 1, Edificio BIC, Armilla, Granada, Spain, Pfizer-Universidad de Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Parque Tecnológico de Ciencias de la Salud (PTS), Avenida de la Ilustración 114, Granada, Spain

David C. Duffy

dduffy@quanterix.com (DCD.); juan@destinagenomics.com (JJD-M)

Affiliation Quanterix Corporation, Lexington, Massachusetts, United States of America

Competing Interests

D.M.R. and D.C.D. are employed by Quanterix Corporation. D.M.R. and D.C.D. own stock in Quanterix Corporation. B.L.-L., S.P., H.I., and J.J.D.-M. are employed by DestiNA Genomics Ltd. S.P., H.I., and J.J.D.-M. own stock in DestiNA Genomics Ltd. H.I. and J.J.D.-M. are members of the board of directors of DestiNA Genomics Ltd. A patent application has been filed based on the work described in this manuscript, with D.M.R., D.C.D., B.L.-L., S.P., H.I., and J.J.D.-M. listed as inventors; Quanterix Corporation and DestiNA Genomics Ltd. are joint assignees of the patent application. Quanterix Corporation and DestiNA Genomics Ltd. plan to develop a kit for commercial sale for performing the miR-122 assay reported here. A.D.B.V. and J.W.D. have no competing interests. This statement does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceptualization: DMR SP HI JWD JJDM DCD. Formal analysis: SP JJDM DCD. Funding acquisition: HI. Investigation: DMR BLL ADBV JWD. Methodology: DMR BLL DCD. Project administration: JJDM. Resources: DMR BLL ADBV JWD. Supervision: SP DCD. Visualization: JJDM DCD. Writing – original draft: DCD. Writing – review & editing: DMR BLL SP HI ADBV JWD JJDM.